期刊文献+

新型二芳基取代-1,2,4-三唑类化合物的抗炎构效关系和分子对接研究 被引量:4

QSAR and docking studies on a new series of diaryl-substituted-1,2,4-trizole de-rivatives COX-2 inhibitors
原文传递
导出
摘要 目的:建立新型二芳基取代-1,2,4-三唑类化合物的定量构效关系,设计新型COX-2抑制剂。方法:采用PM3半经验量子化学法全优化18种二芳基取代-1,2,4-三唑类选择性环氧合酶(COX-2)抑制剂的结构,从数据中搜寻或计算它们的226种参数,利用逐步回归法,建立经典结构一活性关系(2D-QSAR);用Autodock对接软件研究二芳基取代-1,2,4-三唑类化合物与环氧合酶(COX-2)的对接,分析该类化合物与环氧合酶在复合物的立体结构以及分子对接自由能与抑制活性的关系。结果:建立合理二芳基取代-1,2,4-三唑类化合物COX-2抑制剂定量构效关系,表明活性二芳基取代-1,2,4-三唑类选择性环氧合酶(COX-2)抑制剂具有类似塞来昔布等三环类环氧合酶-2抑制剂的立体结构,并且对接自由能与抑制剂活性有较好的相关性。结论:所得的模型可以解释已有的构效关系,而且预测同类化合物能力较好,可指导设计新抑制剂。 AIM :To disclose the quantitative structure-activity relationship of a new series of cyclooxygenase-2 inhibitors, diaryl-substituted-1,2,4-trizole derivatives. Mtehods:The structures of inhibitors were optimized by PM3 semiempirical quantum chemistry meth- ods,and the 2D-QSAR of inhibitors were studied by multiple regression method based on the structure parameters searched from database or theory calculation. These inhibitors docking with the active site in COX-2 were evaluated with Autodock method. Results :These studies produced good predictive 2D-QSAR model. It was found that the structures of diaryl-substituted -1,2,4-trizole derivatives COX- 2 inhibitors are similar to the structures of typical tricyclic cycloxygenase-2 selective inhibitors such as celecoxib, and the inhibitory activities log(l/C) are correlated with docking free energies. Conclusion:The QSAR can explains the dependence of COX-2 inhibiton upon the structures of diaryl-substituted-1,2,4-trizole derivatives. Some structure information for design of new COX-2 inhibitors with higher activity has been given.
出处 《计算机与应用化学》 CAS CSCD 北大核心 2008年第5期603-606,共4页 Computers and Applied Chemistry
关键词 二芳基取代-1 2 4-三唑类化合物 定量构效关系 分子对接 环氧合酶一2 抑制剂 diaryl-substituted-1,2,4-trizole derivatives, QSAR, docking, COX-2, inhibitors
  • 相关文献

参考文献2

二级参考文献15

  • 1Li J,J Med Chem,1995年,38卷,4570页
  • 2Prasit P,Med Chem Res,1995年,5期,364页
  • 3Xie W,Proc Nat Acad Sci USA,1991年,88卷,2692页
  • 4Xie W., Robertson D. L., Simmons D. L. et al.. Drug Dev. Res.[J], 1992, 25(2): 249-265
  • 5Vane J. R.. Nature[J], 1994, 36(2): 215-221
  • 6Vane J. R.. J. Physiol. Pharmacol.[J], 2000, 51: 573-586
  • 7Kampfer H., Brautigam L., Geisslinger G. et al .. J. Invest. Dermatol.[J], 2003, 120(5): 880-886
  • 8Penning T. D., Talley J. J., Bertenshaw S. R. et al.. J. Med. Chem.[J], 1997, 40(9): 1347-1365
  • 9LEIXin-Sheng(雷新胜) ZHUQi-Qing(朱七庆) QULing-Bo(屈凌波).药学学报,1992,12:149-158.
  • 10Mautner H. G., Kumler W. D.. J. Am. Chem. Soc.[J], 1956, 78(1): 97-101

共引文献8

同被引文献39

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部